RVMD ▼ -0.3% - Revolution Medicines, Inc. $RVMD - New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer Revolution Medicines shares dipped 0.3% following publication of Phase 1/2 clinical data on its lead candidate RASONQUE™ in the New England Journal of Medicine, a top-tier medical journal. The modest decline suggests investors may be awaiting additional data or clarity on the drug's commercial potential despite the prestigious venue for the results. 02-SEP-2026 05:50 PM ET